There is no such thing as a manager

I had the opportunity to interview for a senior position at a very big company recently. The entire process was fascinating for what it says about human nature and about large companies. The outcome of the process is unclear at the time of writing this but I am expecting the intrinsic misalignments in the process will lead it into the reeds from which it is unlikely to emerge. I am as close to the perfect candidate for the role that they will ever interview, but the internal parties are not all aligned around the very existence of the position.

Continue reading “There is no such thing as a manager”

Talks cancelled – Talks online

I had quite a nice spring season of talks planned for 2020. I was invited to deliver a keynote on AI in Healthcare at Biovaria. And, I was one of the invited speakers for the Dynamics of Immune Repertoires conference where I would also have given a workshop, in Dresden. Covid-19 struck and the rest is history.

Emergencies lead to quick changes of plans. Anthony Kelly from AI in Action reached out to me asking me to take part in a special on AI in Healthcare.

Continue reading “Talks cancelled – Talks online”

Preprint Announcement – AI in Medicine Product Development Framework

Working in industrial research is usually very motivating but occasionally it is also frustrating. You’ve just done something really cool but you’re not allowed to tell anybody outside the company about it. Indeed, in a small company there might not be anybody inside of the company who can even appreciate it!

I have worked on roughly 4 really cool projects since leaving academia at the end of 2017. And apart from some basic mentions in my blog (e.g. here and here) most of what I have done has been known only to a few key stakeholders.

Since leaving Fosanis last September I have had a visiting researcher affiliation at the Digital Health Accelerator of the Berlin Institute of Health. I have used my time to mentor a cohort of teams attempting to spin out their ideas; to work on a causal inference project; and, to write a paper about the structural aspects of medical AI products. This week, along with my co-author Vince Madai, we submitted that paper.

Continue reading “Preprint Announcement – AI in Medicine Product Development Framework”

Closing a Chapter @ Fosanis

Today is my last official day under contract to Fosanis GmbH. I had my first encounter with the founders following my talk at the Digital Health Forum in March 2018. Following that initial meeting I became an advisor, writing a major funding proposal, bringing scientific techniques to the core of the product. In November 2018, following the closure of my own company, I became a full-time member of staff – as Head of Data Science – and led the project on the basis of the ideas contained in my funding proposal.

Continue reading “Closing a Chapter @ Fosanis”

Entrepreneur First the Index VC Fund

I took part in Entrepreneur First’s (EF’s) first Berlin cohort last summer. I have largely refrained from talking about my experience, even in private so far, but this hasn’t prevented a lot of people from giving me their opinions on the business model of EF.

The EF hypothesis sounds simple: get enough smart and motivated people together in a cohort and give them the opportunity (time, access to funds, etc.) to start businesses together and some of them will succeed…. bigly.

The venture capital community here in Berlin are not so convinced. Personally I sympathise with their doubts. Certainly from an operations point of view, scaling EF has seen problems. However, as a business model it may be genius.

Continue reading “Entrepreneur First the Index VC Fund”

Fosanis: A Brave New Project

I started working at a new job last week. I am now the Head of Data Science at Fosanis GmbH. We’re a startup in Berlin, two years old, and we provide support services for cancer patients. My task is to personalise the approach.

Think personalised medicine, without the medicine. The content we provide has been professionally curated and has been shown to be beneficial to cancer patients. If you speak German, you can try out the content online right now. We will be launching an App-based implementation in the new year.

I want to then take this to the next level. Patients will be treated as a combination of their statistical attributes and their individual trajectories through the interface. From a technological point-of-view, we will be aping many of the approaches pioneered by Facebook. However, we will try to maximise a much trickier to define Quality of Life metric, rather than page refreshes or time spent on the Wall.

This is a really exciting project. I have been looking for a while to find a project where I can apply behavioural modelling approaches to healthcare goals. In a world of rapidly expanding autoimmune diseases I see this ultimately as the new treatment paradigm. What is especially nice is that, in the space in which we are operating there are no real conflicts of interest. I hope that I don’t look back on that statement as hopelessly naive. My impression is that most people in oncology are really trying to make patients’ lives better.

We will be hiring in the first couple of months of 2019, so if you know any talented biological modellers who might be interested, please tell them to email me their CV.